Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Superior Vena Caval Obstruction (SVCO) - Management and Outcome

This study has been completed.
Sponsor:
Collaborator:
Princess Margaret Hospital, Canada
Information provided by:
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00259584
First received: November 28, 2005
Last updated: August 12, 2010
Last verified: August 2010

November 28, 2005
August 12, 2010
October 2001
October 2008   (final data collection date for primary outcome measure)
Improvement in an index symptom at 4 weeks as recorded by a daily symptom diary
- Improvement in an index symptom at 4 weeks as recorded by a daily symptom diary
Complete list of historical versions of study NCT00259584 on ClinicalTrials.gov Archive Site
  • Time to onset of palliation
  • Duration of symptom control
  • Survival
  • Number of days spent in hospital
  • Requirement for further treatment
  • - Time to onset of palliation
  • - Duration of symptom control
  • - Survival
  • - Number of days spent in hospital
  • - Requirement for further treatment
Not Provided
Not Provided
 
Superior Vena Caval Obstruction (SVCO) - Management and Outcome
A Prospective Longitudinal Study of the Management and Outcome of Superior Vena Caval Obstruction (SVCO)

All patients with symptomatic malignant SVCO deemed suitable for treatment either with radiation therapy or by stenting will be eligible. They will receive whichever treatment is deemed most clinically appropriate. Symptomatic response, time to onset of palliation, duration of symptom control and survival will be assessed.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Superior Vena Cava Syndrome
Behavioral: Management and Outcome of SVCO
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
October 2008
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Symptomatic clinical and radiological diagnosis of superior vena caval obstruction.
  • Underlying histological diagnosis deemed appropriate for palliative radiotherapy as treatment by investigator. Patients with chemosensitive tumours such as small cell lung cancer (both untreated and recurrent), lymphoma and testicular tumours, will be eligible if radiation is deemed to be appropriate treatment.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00259584
UHN REB 01-0770-C
Not Provided
Not Provided
University Health Network, Toronto
Princess Margaret Hospital, Canada
Principal Investigator: Andrea Bezjak, MD Princess Margaret Hospital, Canada
University Health Network, Toronto
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP